Use of presepsin and procalcitonin for prediction of SeptiFast results in critically ill patients

Mihajlović, D; Brkić, Snežana; Uvelin, Arsen; Drašković, Biljana; Vrsajkov, Vladimir

doi:10.1016/j.jcrc.2017.04.008

Cited by 21 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our results, PCT concentrations showed a good performance in predicting true-positive REBA Sepsis-ID results, with the AUROC value of 0.72. Our observations were similar to the results of another study, which evaluated the usefulness of PCT concentrations for the prediction of positive SeptiFast results, with the AUROC value of 0.75 (14). PCT concentrations also showed a good performance in predicting true-positive BC results, with the AUROC value of 0.72, similar to the results obtained in other studies, which confirmed a good discriminative power of PCT levels in predicting true-positive BC results (12,45).…”

Section: Discussionsupporting

confidence: 90%

“…Recently, the use of sepsis-associated biomarkers has been recommended to compensate for the limitations of molecular diagnostic assays. Mihajlovic et al (14) reported that presepsin and procalcitonin (PCT) concentrations can predict SeptiFast results and assist in selecting patients who require the SeptiFast test. In this study, we aimed to evaluate the performance of REBA Sepsis-ID using whole-blood samples collected from patients with suspected sepsis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficient Early Diagnosis of Sepsis Using Whole-Blood PCR–Reverse Blot Hybridization Assay Depending on Serum Procalcitonin Levels

Kim

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Sepsis is one of the medical emergencies, and its early detection, within the first hours of development, and proper management improve outcomes. Molecular diagnostic assays using whole blood collected from patients with suspected sepsis have been developed, but the decision making is difficult because of the possibility of false positives, due to contamination. Here, we evaluated the performance of the reverse blot hybridization assay (REBA) Sepsis-ID test for the detection of sepsis-causing microorganisms using whole-blood samples. In addition, the concentrations of Creactive protein (CRP) and procalcitonin (PCT) were determined to evaluate whether these biomarkers can provide criteria for performing REBA Sepsis-ID in clinical settings. For this study, EDTA-anticoagulated whole blood was simultaneously collected for REBA Sepsis-ID and blood culture from 440 patients with suspected sepsis, from January to October 2015. In addition, CRP and PCT concentrations were measured in 227 patients. The overall positive rates of REBA Sepsis-ID and blood culture were 16.6% (73/440) and 13.9% (61/440), respectively. The pathogen-positive rates of REBA Sepsis-ID and blood culture were 9.8% (43/440) and 9.5% (42/440), respectively. The areas under the receiver operating characteristic (AUROC) curves of PCT and CRP for predicting pathogen-positive results of REBA Sepsis-ID were 0.72 and 0.69, respectively. The PCT concentrations in the group of patients aged ≥50 years were significantly higher than those in the group aged <50 years. After adjusting for age, the PCT AUROC value was 0.77 for predicting pathogen-positive results of REBA Sepsis-ID. The optimal cutoff values of PCT concentrations for subsequent application of REBA Sepsis-ID were 0.12 ng/mL in all patients and 0.22 ng/mL in patients aged ≥50 years. Our observations showed that REBA Sepsis-ID using whole blood was advantageous for the early detection of sepsis-causing microorganisms, and the PCT concentration could be used to determine the necessity of using REBA Sepsis-ID in clinical settings. The application of REBA Sepsis-ID using whole blood, based on the PCT concentration, may contribute to a highly efficient detection of sepsis-causing microorganisms.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Efficient Early Diagnosis of Sepsis Using Whole-Blood PCR–Reverse Blot Hybridization Assay Depending on Serum Procalcitonin Levels

Kim

et al. 2020

Front. Med.

View full text Add to dashboard Cite

show abstract

“…This approach showed an improved detection of pathogens in patients with suspected BSI (177). A similar approach in conjunction with neutrophil/lymphocyte count ratios and levels of presepsin and procalcitonin has been suggested (150,178).…”

Section: Modern Nucleic Acid Amplification Technologiesmentioning

confidence: 93%

Emerging Technologies for Molecular Diagnosis of Sepsis

et al. 2018

View full text Add to dashboard Cite

Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern health care. Despite advances in molecular diagnostic techniques, blood culture analysis remains the gold standard for diagnosing sepsis. However, this method is too slow and cumbersome to significantly influence the initial management of patients. The swift initiation of precise and targeted antibiotic therapies depends on the ability of a sepsis diagnostic test to capture clinically relevant organisms along with antimicrobial resistance within 1 to 3 h. The administration of appropriate, narrow-spectrum antibiotics demands that such a test be extremely sensitive with a high negative predictive value. In addition, it should utilize small sample volumes and detect polymicrobial infections and contaminants. All of this must be accomplished with a platform that is easily integrated into the clinical workflow. In this review, we outline the limitations of routine blood culture testing and discuss how emerging sepsis technologies are converging on the characteristics of the ideal sepsis diagnostic test. We include seven molecular technologies that have been validated on clinical blood specimens or mock samples using human blood. In addition, we discuss advances in machine learning technologies that use electronic medical record data to provide contextual evaluation support for clinical decision-making.

show abstract

“…Although Mustafić and co-workers [61] concluded that PCT was a good marker of organ dysfunction, other studies have disputed this, suggesting that SOFA actually outperforms PCT for the prediction of sepsis [70]. PCT does seem to have some use in predicting patients who are eventually diagnosed with bacteraemia [71,72], which is perhaps not surprising considering the mechanism by which PCT rises in response to bacterial infection. A further study that included adult patients in various medical wards also reported similar findings [73], which suggests that this predictive ability is not restricted to the critical care setting.…”

Section: Adults Intensive Care Units (Icu)mentioning

confidence: 99%

“…Most studies in the adult critical care setting have focused on comparing presepsin with PCT. Generally, the performance of presepsin has been described as comparable to that of PCT, with no real advantage gained from using presepsin as a separate, stand-alone biomarker [71,86,87]. This has also been demonstrated in various medical wards outside of the critical care environment [72].…”

Section: Adults Icumentioning

confidence: 99%

Biomarkers for Point-of-Care Diagnosis of Sepsis

2020

View full text Add to dashboard Cite

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In 2017, almost 50 million cases of sepsis were recorded worldwide and 11 million sepsis-related deaths were reported. Therefore, sepsis is the focus of intense research to better understand the complexities of sepsis response, particularly the twin underlying concepts of an initial hyper-immune response and a counter-immunological state of immunosuppression triggered by an invading pathogen. Diagnosis of sepsis remains a significant challenge. Prompt diagnosis is essential so that treatment can be instigated as early as possible to ensure the best outcome, as delay in treatment is associated with higher mortality. In order to address this diagnostic problem, use of a panel of biomarkers has been proposed as, due to the complexity of the sepsis response, no single marker is sufficient. This review provides background on the current understanding of sepsis in terms of its epidemiology, the evolution of the definition of sepsis, pathobiology and diagnosis and management. Candidate biomarkers of interest and how current and developing point-of-care testing approaches could be used to measure such biomarkers is discussed.

show abstract

Use of presepsin and procalcitonin for prediction of SeptiFast results in critically ill patients

Cited by 21 publications

References 35 publications

Efficient Early Diagnosis of Sepsis Using Whole-Blood PCR–Reverse Blot Hybridization Assay Depending on Serum Procalcitonin Levels

Efficient Early Diagnosis of Sepsis Using Whole-Blood PCR–Reverse Blot Hybridization Assay Depending on Serum Procalcitonin Levels

Emerging Technologies for Molecular Diagnosis of Sepsis

Biomarkers for Point-of-Care Diagnosis of Sepsis

Contact Info

Product

Resources

About